If you have Type 2 diabetes, you may be interested in a multisite study that is currently recruiting participants to evaluate the effectiveness of an extended-release version of the oral diabetes drug metformin versus the immediate-release version of the medicine.
To qualify, you must be at least 18 years old and have Type 2 diabetes that is not adequately controlled by diet and exercise alone. People who have a history of diabetic ketoacidosis, lactic acidosis, or hyperosmolar nonketonic coma; symptoms of poorly controlled diabetes; or blood creatinine levels equal to or above 1.50 mg/dl for men and equal to or above 1.40 mg/dl for women are not eligible to participate.
Participants in the study will be assigned to receive either metformin extended-release, metformin immediate-release, or a placebo (inactive treatment) to be taken twice daily for 24 weeks. The researchers will be evaluating the effects of the treatments on A1C levels (a measure of glucose control over the previous 2–3 months), fasting plasma glucose levels, and average daily glucose levels, as well as the safety of the treatments.
For more information about the study, and to find a participating site near you, click here.
And to learn more about metformin, click here to read the article “Metformin: The Unauthorized Biography” by educator Wil Dubois.
This blog entry was written by Web Editor Diane Fennell.